Lupin receives EIR from U.S. FDA for its Somerset Manufacturing Facility

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, with a Voluntary Action Indicated (VAI) status.

The facility was inspected from May 7 to May 17, 2024.

"We are very pleased to have received the EIR with a satisfactory VAI status for our Somerset facility. This is a significant milestone in building our reputation of being best-in-class in Quality and Compliance," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 1559.75 as compared to the previous close of Rs. 1555.10. The total number of shares traded during the day was 13772 in over 1489 trades.

The stock hit an intraday high of Rs. 1578.35 and intraday low of 1531.15. The net turnover during the day was Rs. 21456576.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 EIR USFDA Somerset ManufacturingFacility VAIstatus